Analysts expect Ultragenyx Pharmaceutical Inc. to report revenue of 190.93 M for Q3 26, against a range of 185.09 M to 196.78 M. The most recent reported quarter, Q2 26, came in at 214.00 M, a 23.3% beat against the 173.62 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 139.49 M | 164.88 M | 139.29 M | 166.50 M | 159.93 M | 207.00 M | 136.00 M | 214.00 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 145.68 M | 166.26 M | 143.13 M | 163.36 M | 164.71 M | 222.15 M | 174.24 M | 179.85 M | 196.78 M | 242.36 M | 214.95 M | 256.82 M | 249.54 M | 311.90 M | 237.02 M | 292.37 M | ||||||||||
| Low Estimate | 119.32 M | 150.77 M | 131.79 M | 146.21 M | 152.39 M | 187.32 M | 158.95 M | 167.39 M | 185.09 M | 220.08 M | 195.78 M | 223.49 M | 219.75 M | 275.60 M | 207.93 M | 269.56 M | ||||||||||
| Consensus Estimate | 132.50 M | 158.51 M | 137.46 M | 154.79 M | 158.55 M | 204.74 M | 166.59 M | 173.62 M | 190.93 M | 231.22 M | 205.36 M | 240.15 M | 234.65 M | 293.75 M | 222.47 M | 280.96 M |
Analysts expect Ultragenyx Pharmaceutical Inc. to report earnings per share of -0.95 for Q3 26, against a range of -0.99 to -0.91. The most recent reported quarter, Q2 26, came in at -0.90, a 30.8% beat against the -1.30 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.40 | -1.39 | -1.57 | -1.17 | -1.81 | -1.29 | -1.84 | -0.90 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -1.42 | -1.27 | -1.58 | -1.29 | -1.20 | -0.96 | -1.31 | -1.23 | -0.91 | -0.24 | -0.64 | -0.26 | -0.36 | 0.34 | -0.26 | 0.15 | ||||||||||
| Low Estimate | -1.72 | -1.49 | -1.76 | -1.49 | -1.34 | -1.12 | -1.57 | -1.37 | -0.99 | -0.26 | -0.78 | -0.28 | -0.40 | 0.30 | -0.30 | 0.13 | ||||||||||
| Consensus Estimate | -1.57 | -1.38 | -1.67 | -1.39 | -1.27 | -1.04 | -1.44 | -1.30 | -0.95 | -0.25 | -0.71 | -0.27 | -0.38 | 0.32 | -0.28 | 0.14 |
Pull Wall Street consensus for Ultragenyx Pharmaceutical Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=RARE&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "RARE", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=RARE&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();